Details for New Drug Application (NDA): 202189
✉ Email this page to a colleague
The generic ingredient in BUPROPION HYDROCHLORIDE is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-five suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
Summary for 202189
Tradename: | BUPROPION HYDROCHLORIDE |
Applicant: | Wockhardt Ltd |
Ingredient: | bupropion hydrochloride |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 202189
Mechanism of Action | Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors |
Physiological Effect | Increased Dopamine Activity Increased Norepinephrine Activity |
Suppliers and Packaging for NDA: 202189
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 202189 | ANDA | Wockhardt USA LLC. | 64679-102 | 64679-102-01 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64679-102-01) |
BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 202189 | ANDA | Wockhardt USA LLC. | 64679-102 | 64679-102-02 | 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (64679-102-02) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 150MG | ||||
Approval Date: | Nov 21, 2012 | TE: | AB3 | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 300MG | ||||
Approval Date: | Jan 28, 2022 | TE: | AB3 | RLD: | No |
Complete Access Available with Subscription